SIU Congress 2016: Effect of Gonadotrophin-Releasing Hormone Analogue-Induced Follicle-Stimulating Hormone Suppression on Prostate-Specific Antigen Response - Poster


  • Follicle-stimulating hormone (FSH) has been indicated in the development and progression of prostate cancer.
  • Coupled with testosterone suppression to castration levels, FSH suppression may delay disease progression, and improve prognosis. 
  • Degarelix, a gonadotropin-releasing hormone (GnRH) antagonist, has been associated with rapid and profound testosterone and FSH suppression along with prostate specific antigen (PSA) suppression.
  • Here we present the factors predicting the FSH suppression including ′on treatment′ PSA suppression from an already published study. 

SIU 2016 Poster layout Thumb
Click Image to Enlarge